Inmune Bio (INMB) Cash from Financing Activities (2018 - 2025)

Inmune Bio has reported Cash from Financing Activities for 8 years, with the latest figure at $67000.0 in Q4 2025.

• Quarterly Cash from Financing Activities rose 103.22% year-over-year to $67000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $27.6 million (up 51.62% YoY) and the FY2025 annual result came in at $27.6 million, up 51.62% from the prior year.
• Cash from Financing Activities declined to $67000.0 in Q4 2025 per INMB's latest filing, from $22.3 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $52.9 million in Q3 2021 and troughed at -$2.5 million in Q4 2023.
• A 5-year average of $11.7 million and a median of $7.5 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2021 and 2022: Cash from Financing Activities soared 316366.67% in 2021, then tumbled 97.44% in 2022.
• Over 5 years, Cash from Financing Activities stood at $52.9 million in 2021, then sank by 98.62% to $729000.0 in 2022, then plunged by 442.94% to -$2.5 million in 2023, then grew by 16.88% to -$2.1 million in 2024, then soared by 103.22% to $67000.0 in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $67000.0, $22.3 million, and $5.3 million for Q4 2025, Q2 2025, and Q1 2025 respectively.